Filing Flows › Opko Health (OPK) › Q2 2026 › vs Q1 2026
Opko Health (OPK) Q2 2026 vs Q1 2026 (quarter over quarter)
Opko Health's revenue rose $39.4M (+32%) from $124M in Q1 2026 to $164M in Q2 2026. The biggest changes: Intellectual Property and Other +$32.1M (+229%); Product +$4.9M (+13%); Service +$2.4M (+3%).
Opko Health, Q2 2026: revenue $164M (+4% year over year), operating margin -4.3%, net loss $8.4M, operating cash flow −$43.5M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Service | $74.5M | $72.2M | $2.4M | +3% |
| Intellectual Property and Other | $46.1M | $14.0M | $32.1M | +229% |
| Product | $42.9M | $38.0M | $4.9M | +13% |
| Revenue | $164M | $124M | $39.4M | +32% |
| Income tax benefit | $5.0M | $6.1M | −$1.1M | -18% |
| Net loss | $8.4M | $54.8M | −$46.4M | -85% |
| Costs & expenses | $177M | $185M | −$8.2M | -4% |
| Operating costs | $171M | $175M | −$4.7M | -3% |
| Interest & other, net | $6.4M | $9.9M | −$3.5M | -35% |
| Cost of revenue | $83.6M | $78.4M | $5.1M | +7% |
| Research & development | $33.2M | $29.2M | $4.0M | +14% |
| SG&A | $52.9M | $48.6M | $4.3M | +9% |
| Other operating costs | $899K | $19.0M | −$18.1M | -95% |
| Operating cash sources | $68.1M | $44.2M | $23.9M | +54% |
| Depreciation & amortization | $22.4M | $22.2M | $208K | +0.9% |
| Share-based compensation | $2.2M | $2.7M | −$535K | -20% |
| Cash used in operations | $43.5M | $19.3M | $24.2M | +125% |
| Net loss absorbed | $8.4M | $54.8M | −$46.4M | -85% |
| Working capital & other | $59.7M | −$10.6M | $70.3M | — |
Questions
How much did Opko Health's revenue grow quarter over quarter in Q2 2026?
Opko Health's revenue rose $39.4M (+32%) from $124M in Q1 2026 to $164M in Q2 2026.
What drove Opko Health's revenue change in Q2 2026?
Intellectual Property and Other +$32.1M (+229%); Product +$4.9M (+13%); Service +$2.4M (+3%).